TXG (TXG) Stock Forecast: What Could Drive It in 2026
Short answer
What is actually driving TXG (TXG) right now is Consumables-led recurring revenue: Even with instrument sales frozen, consumables grew about 13% year over year in Q1 2026 as the large installed base of Chromium and spatial instruments keeps ordering reagents. Revenue (TTM) is ~$639M. If that keeps playing out, the setup is favourable; the risk to it is the biggest overhang is demand: U.S. No one can predict where TXG trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive TXG (TXG) higher?
1. Consumables-led recurring revenue
Even with instrument sales frozen, consumables grew about 13% year over year in Q1 2026 as the large installed base of Chromium and spatial instruments keeps ordering reagents. This recurring, higher-margin revenue is the ballast that helped lift gross margin toward 70% and narrow losses. A growing installed base compounds this stream over time.
2. New platform launches (Atera and spatial)
10x launched the Atera in situ platform in April 2026, promising whole-transcriptome spatial analysis at single-cell resolution, with shipments starting in the second half of the year. Xenium and Visium continue to expand the spatial franchise. New instruments both seed future consumables pull-through and defend the company's technology leadership.
3. Market leadership and consolidation
10x is the recognized leader across single-cell and spatial biology, and the space has consolidated (former rival NanoString went through bankruptcy and is now Bruker Spatial). That created an opening to capture displaced customers. The company is also pushing single-cell technology toward clinical and diagnostic applications, a potential longer-term expansion beyond research.
4. Margin and cost discipline
Operating expenses fell about 15% year over year in Q1 2026 on lower legal, personnel, and marketing costs, and gross margin rose on fewer inventory write-downs and warranty charges. With roughly $540M of cash and no debt, the company has runway to fund launches while it works toward sustained profitability.
What could weigh on TXG?
The biggest overhang is demand: U.S. academic and NIH-linked research funding plus biopharma capital budgets have tightened sharply, and instrument sales dropped about 24% year over year, driving management's flat guidance. The company is still unprofitable on a net basis, so the valuation (price-to-sales near 7x) leans heavily on a growth reacceleration that may not arrive on schedule. Competition is intensifying from Illumina, Bruker Spatial, Bio-Techne, Akoya, Vizgen, Bio-Rad, and newer single-cell entrants, and 10x has a long history of patent litigation whose settlements produced non-recurring revenue that will not repeat. New-platform adoption (Atera) is unproven at scale, and results can be lumpy quarter to quarter.
Where TXG trades today
A forecast starts from where the stock actually is. These are TXG's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for TXG as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a TXG forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the TXG guide and whether TXG is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the TXG outlook
The bottom line: what is driving TXG (TXG) is Consumables-led recurring revenue, with revenue (ttm) at ~$639M. If that keeps playing out the setup is favourable; the risk is the biggest overhang is demand: U.S. No one can predict the price, so treat any TXG forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around TXG with Walnut
Use TXG as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for TXG (TXG)?
+
No one can reliably predict where TXG will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push TXG higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive TXG higher?
+
The main growth drivers are Consumables-led recurring revenue; New platform launches (Atera and spatial); Market leadership and consolidation. Whether they play out is the real question, not a guaranteed path.
What are the risks to TXG?
+
The biggest overhang is demand: U.S. academic and NIH-linked research funding plus biopharma capital budgets have tightened sharply, and instrument sales dropped about 24% year over year, driving management's flat guidance. The company is still unprofitable on a net basis, so the valuation (price-to-sales near 7x) leans heavily on a growth reacceleration that may not arrive on schedule. Competition is intensifying from Illumina, Bruker Spatial, Bio-Techne, Akoya, Vizgen, Bio-Rad, and newer single-cell entrants, and 10x has a long history of patent litigation whose settlements produced non-recurring revenue that will not repeat. New-platform adoption (Atera) is unproven at scale, and results can be lumpy quarter to quarter.
Will TXG stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. TXG's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is TXG a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the TXG "is it a buy?" page for a framework. Walnut is not an investment adviser.
How fast is 10x Genomics growing?
+
Slowly right now. Full-year 2026 guidance of about $600M to $625M implies only 0% to 4% growth after excluding one-time patent-settlement revenue. Consumables grew about 13% in Q1, but instrument sales fell around 24% as research budgets tightened, holding overall growth back.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.